LNTH — Lantheus Holdings Share News
0.000.00%
Last trade - 00:00- $7.15bn
- $7.22bn
- $1.54bn
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports (updated)
Lantheus weighs potential $7 billion sale, Bloomberg News reports
Brief: Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium - Bloomberg News
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Lantheus Q1 revenue rises 1.2%, beats expectations
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
Lantheus falls as FDA extends review of experimental cancer diagnostic
Brief: Lantheus Announces Three-Month Extension Of PDUFA Date For LNTH-2501
US FDA extends review of Lantheus' diagnostic imaging kit by three months (updated)
US FDA extends review of Lantheus' diagnostic imaging kit by three months
US FDA approves Lantheus' new prostate cancer imaging formulation (updated)
Brief: Lantheus Announces FDA Approval Of Pylarify TruVu™ (piflufolastat F 18) Injection
US FDA approves Lantheus’ new prostate cancer imaging formulation
Brief: Lantheus Receives FDA Tentative Approval For Lutetium Lu 177 Dotatate (Pnt2003), Radioequivalent To Lutathera®